Related Experiment Video

Updated: Mar 16, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Associations between antiretroviral use and subclinical coronary atherosclerosis

Guajira P Thomas1, Xiuhong Li, Wendy S Post

  • 1aDivision of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health cDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland dLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California eDepartment of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.

AIDS (London, England)
|August 5, 2016
PubMed

Insights

For HIV-infected men with suppressed virus, specific antiretroviral therapy (ART) drugs were not consistently linked to coronary plaque. This suggests ART type may not be a major factor in subclinical coronary plaque risk for these individuals.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • HIV infection is linked to a higher prevalence of subclinical coronary plaque.
  • The influence of HIV itself versus long-term antiretroviral therapy (ART) on this plaque is not well understood.

Purpose of the Study:

  • To investigate the association between specific ART drugs and the presence/extent of coronary plaque in HIV-infected men.
  • To determine if ART type is a significant factor in subclinical coronary plaque risk.

Main Methods:

  • Coronary computed tomography (CT) was used to assess plaque and stenosis in HIV-infected men.
  • Fully adjusted logistic and linear models with inverse probability of treatment weighting were employed to control for confounders.

Main Results:

  • Cumulative use of zidovudine, abacavir, darunavir, and protease inhibitors showed inconsistent associations with coronary plaque.
  • No consistent links were found between specific ART drugs and subclinical coronary plaque presence or extent in virally suppressed men.

Conclusions:

  • Among virally suppressed HIV-infected men, specific ART drug use does not appear to be a primary driver of subclinical coronary plaque.
  • Findings suggest that ART type is generally not a major determinant of coronary plaque risk in this population.
Abstract

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
700
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
378
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
516
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
798
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564